
---
nice.evidencecategory: 
---

### Evidence Statement CG66ES187
This single centre, double-blind study compared fenofibrate 160 mg/day with simvastatin 20 mg/day and both monotherapies with the combination of fenofibrate and simvastatin, with N=300 participants.298 Fenofibrate was found to have significantly greater reductions in TC and for LDL-C than simvastatin and than the combination of the drugs, differences between simvastatin and the combined group were NS.  The fenofibrate and combined groups had significantly higher decreases in TGs than simvastatin (NS between fenofibrate and combined treatments). 
Adverse events
There were no serious drug related AEs. Level 1++

[@Muhlestein_2006]

